Deanol, lithium and placebo in the treatment of tardive dyskinesia. A double-blind crossover study.
A double-blind crossover study on the effects of deanol and lithium carbonate was conducted on a sample of 29 chronic schizophrenic patients with tardive dyskinesia. In addition to his usual treatment with different neuroleptics, each patient received during an 8-week period either deanol, lithium carbonate or placebo. A 4-week wash-out period was inserted between each of the 8-week periods of experimental treatment of the tardive dyskinesia. The administration of either deanol, lithium carbonate or placebo added to the neuroleptic treatment did not produce a statistically significant improvement of tardive dyskinesia in our patient population as a whole. Favorable and unfavorable responses are discussed.
D000328:Adult; D002986:Clinical Trials as Topic; D003642:Deanol / Q000008:administration & dosage / Q000627:therapeutic use*; D004311:Double-Blind Method; D004341:Drug Evaluation; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy*; D004562:Electrocardiography; D004569:Electroencephalography; D004983:Ethanolamines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008094:Lithium / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000188:drug therapy
D004983:Ethanolamines; D010919:Placebos; D003642:Deanol; D008094:Lithium